Imipenem is a beta-lactam antibacterial with a broad-spectrum of activity against Gram-positive, Gram-negative bacteria, and anaerobes. It is administered in combination with cilastatin, a specific enzyme inhibitor, which blocks imipenem's partial inactivation by enzymatic activity in the kidney.
severe hospital-acquired infectionspolymicrobial infectionssepticaemiahospital-acquired pneumoniaintra-abdominal infectionsskin and soft-tissue infectionscomplicated urinary-tract infectionsinfections with Pseudomonas aeruginosaNosocomial infections: pneumonia, intra-abdominal infections, urinary tract infectionsUrinary tract infectionsLower respiratory infectionsIntra-abdominal and gynecological infectionsSkin, soft-tissue, bone, and joint infectionsEmpirical treatment of serious infections in hospitalized patients at risk for resistant pathogensmultidrug-resistant tuberculosismycobacterium abscessus (in combination)
- Adult
- penicillin cost several dollars per 100,000 units; today, the same dose. equals 1667 units; 1.0 mg of pure penicillin G potassium represents. 1595 units. The dosage and the antibacterial potency of the semisynthetic penicillins are expressed in terms of weight.
- Renal adjustment
- Reduce dose only in moderate-severe failure
Metabolism
Partially inactivated in the kidney by enzymatic activity; co-administered with cilastatin to block renal metabolism.
- Infections caused by meticillin-resistant Staphylococcus aureus
- Infections caused by Enterococcus faecium
Common
Side-effects similar to those of other beta-lactam antibioticsDiarrhoeaVomitingSkin rashesHypersensitivity reactionsGastrointestinal side effects (e.g., diarrhea)
Serious
- Seizures (at higher doses and in predisposed patients)
- Hypersensitivity reactions (rash to anaphylaxis)
- Serum sickness
- Stevens-Johnson syndrome
- Nephropathy
- Hematologic reactions (neutropenia, prolonged use)
- Neurotoxicity (more commonly described, seizure, high doses, renal impairment)
Drug interaction classified as: synergy
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Valproic AcidSevere
Database
Clinical effect not specified
Source: DDInter
CilastatinModerate
Textbook
Increased renal availability and efficacy of imipenem.
Cilastatin is co-administered with imipenem in a fixed combination to enhance its therapeutic effect.
Source: KDT 7e · p35
6 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.